Abstract 14842: Concordance Between the Various Cardiovascular Risk Scores: Six Months Results of the Randomised Clinical Trial Evaluating Whole-Body Digital Twin Technology Enabled Precision Nutrition for Remission of Diabetes

Abstract

Introduction: The Twin Precision Treatment (TPT) intervention uses the Whole-Body Digital Twin Platform, with AI and the Internet of Things, to integrate multi-dimensional data to give precision nutrition and health recommendations via the TPT app and by coaches Methods: We compared the differences between the cardiovascular (CV) risk scores: (ASCVD (atherosclerotic cardiovascular disease) risk score, QRISK, and Framingham risk score (FRS) in the TWIN intervention arm (T) (n=203) and control group (C) (n=80) along with the changes in glycemic and extra glycemic parameters Results: Mean age (years) in T and C was 43.4 (±8.2) and 50.9 (±10.6); respectively. Mean duration of diabetes (years) in T and C was 3.7 (±2.6) and 4.7 (±2.8); respectively. There was a significant reduction in all three risk scores in T arm with glycemic and other extra glycemic parameters (Table). In the intervention arm, the mean difference in the ASCVD score (%) from baseline to 180 days was comparable in the group that achieved remission (AR) (n=170) -5.3 (±5.7, 95% CI -6.2 to -4.4) and the group that did not achieve remission (DAR) (n=33) -3.9 (±4, 95% CI -5.3 to -2.5) (p=019 ns). Similarly, the mean difference in the QRISK score (%) from baseline to 180 days was comparable in AR -3.3 (±5.1, 95% CI -4.1 to -2.5) and DAR -5.1 (±6.7, 95% CI -7.6 to -2.7), (p=0.07 ns). Mean difference in the FRS (%) from baseline to 180 days was comparable in AR -9.2 (±7.4, 95% CI -10.4 to -8.1) and DAR -7.4 (±6.9, 95% CI -9.8 to -4.9), (p=0.18 ns). On day 180 Kappa agreement between ASCVD and QRISK was 0.32, between QRISK and FRS was 0.63, and between ASCVD and FRS was 0.43. Conclusions: The significant reduction in all three CV risk scores at three months was sustained at six months. TPT yields a significant reduction in cardiovascular risk across the three risk scores and is independent of the achievement of remission of diabetes. TPT, apart from achieving diabetes remission, has independent benefits for the reduction of cardiovascular risk.